Micromedic Technologies Ltd. (TASE:MCTC) portfolio company Biomed Technologies Ltd. today reported success in its clinical trial to test the feasibility of innovative technology developed at the University of Florida for the diagnosis of cancer of the upper digestive tract, large intestine, and small intestine.
The technology located epithelial malignant cells.
The trial was based on 30 biopsy samples which were tested by the new technology. The results were compared with morphological test results. The Biomed technology was able to discern between cancer and healthy cases in 100% of tests, and was able to identify over 85% of cases of various pre-cancerous cells (dysplastic cells).
On the basis of the test results, Biomed Technologies intends to pursue the development of a diagnostic kit for the detection of epithelial malignant cells at early and pre-cancer stages. Development of the diagnostic kit will include extensive clinical trials, the results of which the company does not expect until the second half of 2009 at the earliest.
Biomed has a research agreement with the University of Florida.
Published by Globes [online], Israel business news - www.globes-online.com - on January 18, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009